AstraZeneca: Real-World Evidence at ECCMID 2024 Further Substantiates the Continued Significant and Disproportionate Risk of Severe COVID-19 Facing Immunocompromised Individuals
April 27, 2024
April 27, 2024
WILMINGTON, Delaware, April 27 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
New real-world data from AstraZeneca re-affirms the significant and disproportionate burden of COVID-19 on immunocompromised patients compared to the general population despite vaccination, underscoring the need for additional protection for these vulnerable populations.
The data from INFORM and COVIDRIVE is being presented at the European Society of C . . .
New real-world data from AstraZeneca re-affirms the significant and disproportionate burden of COVID-19 on immunocompromised patients compared to the general population despite vaccination, underscoring the need for additional protection for these vulnerable populations.
The data from INFORM and COVIDRIVE is being presented at the European Society of C . . .